...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatic diseases clinics of North America >Idiopathic inflammatory myopathy: management and prognosis.
【24h】

Idiopathic inflammatory myopathy: management and prognosis.

机译：特发性炎性肌病：治疗和预后。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We are entering an exciting era in our understanding and management of the connective tissue diseases and, in particular, inflammatory myopathy. There is an established array of immunosuppressive regimens available to clinicians; rehabilitative and physical therapeutic interventions are evolving to provide many nonpharmacologic options to complement current therapy. Our ability to quantify [table: see text] the disease burden, using newly developed tools to distinguish myositis disease activity from disease damage, will allow us to measure with greater sensitivity the effects of treatment interventions. These measures, together with the development of international consensus regarding the standardization of many clinical trial design parameters, will enhance our capacity to conduct well-designed, prospective, multicenter studies of established and newly developed therapies. The explosion of immunopathogenetic information, in conjunction with novel biologic agents (Table 4), will afford investigators a treatment menu with multiple therapeutic options. The continuing challenge for the practitioner is the development of a logical, well-studied, multifaceted, and multidisciplinary holistic approach that optimizes the risk: benefit ratio for each individual patient and uses a rational combination of immunomodulatory agents in conjunction with ancillary measures.
机译：我们对结缔组织疾病，尤其是炎症性肌病的理解和管理正进入令人兴奋的时代。临床医生可以使用一系列成熟的免疫抑制方案。康复和物理治疗干预措施正在发展，以提供许多非药物选择来补充当前的治疗方法。我们使用新开发的工具来区分肌炎疾病活动与疾病损害的量化疾病负担的能力，将使我们能够更敏感地衡量治疗干预措施的效果。这些措施以及有关许多临床试验设计参数标准化的国际共识的发展，将增强我们对已建立和新开发的疗法进行精心设计，前瞻性，多中心研究的能力。免疫病理信息的激增，再加上新型生物制剂（表4），将为研究人员提供具有多种治疗选择的治疗菜单。从业人员面临的持续挑战是，开发一种逻辑，经过充分研究，多方面和多学科的整体方法，以优化每个患者的风险：获益比，并结合合理的免疫调节剂和辅助措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号